Mireille Prince-David

TL;DR: Salou et al. as mentioned in this paper determined virological outcome in perinatally HIV-1-infected children and adolescents receiving ART in Togo, where the median duration on ART was 48 months (interquartile range: 28 to 68 months).

TL;DR: The high number of resistant strains observed in Togo shows clearly that the emergence of HIV drug resistance is of increasing concern in countries where ART is now widely used, and can compromise the long-term success of first- and second-line ART.

TL;DR: The study shows the high prevalence of HBsAg carriage in young people, which could be used to enhance prevention and treatment of HBV infection in Togo.

TL;DR: In 767 patients attending routine HIV centers in Togo and receiving first-line ART for more than four years, 42% had viral load greater than 1000 copies/ml and either were on a completely ineffective ART regime or were with only a single drug active.

TL;DR: High inter-laboratory concordance rates as well as case confirmation rates of 50% (microscopy), 71% (PCR at national level), and 78% (including qPCR confirmation at external reference laboratory) suggest high standards of BUD diagnostics.